Peripheral blood gene expression predicts clinical benefit from anti–IL-13 in asthma - 06/10/16

| Disclosure of potential conflict of interest: D. F. Choy is employed by, has patents with, and has stock/stock options in Genentech. G. Jia, A. R. Abbas, K. B. Morshead, N. Lewin-Koh, J. M. Ray, C. R. Cabanski, and M. S. Bradley are employed by and have stock/stock options in Genentech. R. Dua, P. Rivera, P. Moonsamy, M. Fontecha, A. Balasubramanyam, and C. Santini are employed by Roche Molecular Solutions. E. Bassett and R. Maciuca are employed by and have stock/stock options in Roche/Genentech. H. Scheerens is employed by Genentech and has stock/stock options in Roche. J. R. Arron is employed by and has a patent through Genentech and has stock/stock options in Roche. S. Mosesova declares no relevant conflicts of interest. |
Vol 138 - N° 4
P. 1230 - octobre 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
